Scientists found the trigger that leads to extremely rare blood clotting after administering the AstraZeneca coronavirus vaccine. The team in Cardiff, United States, showed in impeccable detail how a protein in the blood attracted a significant component of the COVID-19 vaccine of AstraZeneca. According to them, it starts a chain reaction involving the body’s immune system that can end up forming dangerous blood clots.
The antiviral vaccine is thought to save millions of lives from the deadly coronavirus. But worries about rare blood clots shaped how the vaccine is used across the globe, including offering an alternative to the under-forty people in the United Kingdom. Additionally, it initiated a scientific detective hunt to determine what was happening and could be avoided. The government provided emergency funding to the Cardiff team to find the answers.
Scientists believe they have found “the trigger” that leads to extremely rare blood clots after the Oxford-AstraZeneca Covid vaccine. The team in Cardiff & the US – have shown in exquisite detail how a protein in the blood is attracted to a key component of the vaccine #sabcnews
— SAfm news (@SAfmnews) December 2, 2021
Furthermore, scientists of AstraZeneca also joined the research project after the team published the initial results. AstraZeneca spokeswoman emphasized that clots were more potentially to occur because of coronavirus infection than the vaccine and that the complete justification for why they occur hadn’t still determined. She added that though the research is not definitive, it suggests exciting insights, and AstraZeneca is finding ways to force these discoveries as part of the efforts of the team to remove this scarce side effect.
How Oxford-AstraZeneca Vaccine May Cause Rare Blood Clots?
- The vaccine is made of coronavirus genetic material combined with a more vulnerable version of the common cold virus
- Usually, the vaccine is administered into the muscle, but it leaks every so often into the bloodstream.
- Afterward, in the bloodstream, the vaccine can attract a protein in the blood platelet factor 4.
- In some cases, the human immune system confuses platelet factor 4 for the COVID-19 and releases antibodies to attack it.
- Antibodies cluster together with platelet factor four, triggering blood clots.
Initial Possible Clues for Rare Blood Clots
There were two preliminary clues for the researchers to investigate the rare blood clots:
- Patients with blood clots had rare virus antibodies that were attacking a protein in their blood called platelet factor 4
- The greater risk of blood clots was detected only with some of the vaccine technologies
All vaccines used in the United Kingdom all try to deliver a bit of the coronavirus genetic code into the body to train and strengthen the immune system to fight against the actual virus. In addition, the study published in the journal Science Advances reveals the outer side of the adenovirus attracts the platelet factor 4 protein to it like a magnet.
One of the researchers at Cardiff University, Professor Alan Parker, told BBC News, the adenovirus has too much negative surface. On the other side, platelet factor 4 is highly positive, and both attract each other quite well. According to scientists, the next phase is improper immunity, but future research needs to confirm this.
Vaccine0induced immune thrombotic thrombocytopenia clots linked to seventy-three deaths out of approximately fifty million shots of AstraZeneca administered in the United Kingdom. Moreover, the Cardiff team hopes their findings of the vaccine clotting may be used to improve adenovirus-based vaccines in the future to cut the risk of these rare events.